OnQuality Pharmaceuticals – Phase 2 Cancer Supportive Care Therapy For Hand Foot Skin Reaction

Dr. Michael McCullar, CEO, and Dr. Hong Tang, Chief Medical Officer at OnQuality Pharmaceuticals, a clinical stage pharma company pioneering the discovery and development of targeted cancer supportive care therapies that address cancer treatment-related toxicities at the molecular level, discuss the company’s lead pipeline candidate, OQL011, the first targeted treatment for the severe cancer med side effect Hand Foot Skin Reaction (HFSR). OQL011 is currently in Phase 2 study at onco-dermatology clinics across the country. It is a topical ointment that can be applied to the hands and feet, acting locally to restore VEGFR signaling while avoiding any interference with the main cancer med mechanism of action.  

Michael McCullar is the Chief Executive Officer of OnQuality Pharmaceuticals. He has more than 20 years of pharmaceutical experience in strategic planning and development, drug discovery and operation, business development and commercial operation. Previously he served as Chief Operating Officer at Tolero Pharmaceuticals, where he oversaw drug discovery and development activities as well as corporate development, and commercial planning. He played a major role in the acquisition of Tolero by Sumitomo Dainippon Pharma for $780M ($200M upfront). Prior to joining Tolero Pharmaceuticals, he held multiple roles at Astex Pharmaceuticals including Senior Vice President of Business Development where he was involved in the acquisition of Astex Pharmaceuticals by Otsuka for $886M in cash. In addition, he served as Vice President of Development and Operations and led the FDA approval of Dacogen for the treatment of MDS, while at SuperGen, Inc. Dr. McCullar earned a PhD from the University of California and an MBA from the W.P. Carey School of Business, Arizona State University.

Dr. Hong Tang, Chief Medical Officer, and co-founder of OnQuality Pharmaceuticals. Hong is a Board-certified physician with more than 15 years’ experience in both drug development and medical affairs, and conducted all phases of clinical trials. She served as VP, Executive Medical Director, Medical Director, and Medical Officer in Dendreon, Juno, Astellas, BMS and NIH.

Listen on Soundcloud.